IO Biotech, Inc. Common Stock (IOBT) Stock Price
IOBTStock
$0.00−56.34%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta-0.14
IOBT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-111.90%
Price vs S&P 500 (4W)-91.54%
VGM Score18.46
IOBT Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.60
2.60
2.50
2.50
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IOBTIO Biotech, Inc. Common Stock | — | — | F | $0.00 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About IO Biotech, Inc. Common Stock
IO Biotech is a clinical-stage biopharmaceutical company developing cancer vaccines using its proprietary T-win technology platform. The company's approach targets multiple immunosuppressive pathways to enhance the immune system's ability to recognize and attack cancer cells. This dual-pathway targeting strategy aims to overcome a key mechanism by which tumors evade immune response.